Basic Information
| LncRNA/CircRNA Name | NKILA |
| Synonyms | AK056098 |
| Region | GRCh38_20:57710183-57712780 |
| Ensemble | ENSG00000278709 |
| Refseq | NR_131157 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | T cell | Survival | ||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Microarray, Luciferase reporter assay, RNAi, RIP, other |
| Sample | breast cancer tisuees and autologous tumor cells and HLA-A2+ cancer cell lines24,25,50 (MDA-MB-231, MCF7, NCI-H1703, or PC-9), blood |
| Expression Pattern | NA |
| Function Description | Mechanistically, calcium influx in stimulated T cells via T cell-receptor signaling activates calmodulin, thereby removing deacetylase from the NKILA promoter and enhancing STAT1-mediated transcription. Administering CTLs with NKILA knockdown effectively inhibited growth of breast cancer patient-derived xenografts in mice by increasing CTL infiltration. Clinically, NKILA overexpression in tumor-specific CTLs and TH1 cells correlated with their apoptosis and shorter patient survival. |
| Pubmed ID | 30224822 |
| Year | 2018 |
| Title | NKILA lncRNA Promotes Tumor Immune Evasion by Sensitizing T Cells to Activation-Induced Cell Death |
External Links
| Links for NKILA | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |